- Home
- ALLO vs DFDV Comparison
ALLO vs DFDV Comparison
Compare ALLO & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- DFDV
- Stock Information
- Founded
- ALLO 2017
- DFDV 2018
- Country
- ALLO United States
- DFDV United States
- Employees
- ALLO N/A
- DFDV N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- DFDV Finance: Consumer Services
- Sector
- ALLO Health Care
- DFDV Finance
- Exchange
- ALLO Nasdaq
- DFDV Nasdaq
- Market Cap
- ALLO 363.1M
- DFDV 340.7M
- IPO Year
- ALLO 2018
- DFDV N/A
- Fundamental
- Price
- ALLO $1.40
- DFDV $16.07
- Analyst Decision
- ALLO Strong Buy
- DFDV Buy
- Analyst Count
- ALLO 9
- DFDV 1
- Target Price
- ALLO $8.44
- DFDV $45.00
- AVG Volume (30 Days)
- ALLO 3.5M
- DFDV 2.4M
- Earning Date
- ALLO 08-06-2025
- DFDV 08-12-2025
- Dividend Yield
- ALLO N/A
- DFDV N/A
- EPS Growth
- ALLO N/A
- DFDV N/A
- EPS
- ALLO N/A
- DFDV N/A
- Revenue
- ALLO N/A
- DFDV $1,975,695.00
- Revenue This Year
- ALLO N/A
- DFDV $70.03
- Revenue Next Year
- ALLO $199.63
- DFDV $142.86
- P/E Ratio
- ALLO N/A
- DFDV N/A
- Revenue Growth
- ALLO N/A
- DFDV 1.47
- 52 Week Low
- ALLO $0.86
- DFDV $0.48
- 52 Week High
- ALLO $3.78
- DFDV $53.88
- Technical
- Relative Strength Index (RSI)
- ALLO 54.41
- DFDV N/A
- Support Level
- ALLO $1.21
- DFDV N/A
- Resistance Level
- ALLO $1.31
- DFDV N/A
- Average True Range (ATR)
- ALLO 0.11
- DFDV 0.00
- MACD
- ALLO 0.02
- DFDV 0.00
- Stochastic Oscillator
- ALLO 40.82
- DFDV 0.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.